A British-American team of scientists claims to have found the “trigger” behind clot formation in certain patients immunized with the AstraZeneca Covid-19 vaccine.
The researchers discovered that the protein implicated in thrombosis “is capable of forming stable complexes with clinically relevant adenoviruses.” The immune system can confuse blood protein (platelet factor 4) with the virus and release antibodies to attack it. The antibodies and platelet factor 4 can then clump together, triggering blood clots.
The study was published in the Science Advances journal on Wednesday. According to its authors, the finding represents “an important step in unraveling the mechanisms” underlying the thrombosis with thrombocytopenia syndrome that sometimes develops after the use of the adenovirus-based vaccine.
The researchers underline that cases of blood clots are “ultrarare” because many complicated factors must coincide for them to occur.
AstraZeneca scientists also took part in the research, joining in at a later stage. “Although the research is not definitive, it offers interesting insights and AstraZeneca is exploring ways to leverage these findings as part of our efforts to remove this extremely rare side effect,” a spokeswoman for the company said, as quoted by BBC.
According to UK government numbers, reported this summer, the estimated overall incidence of blood clots is around 14.9 per million doses of the vaccine.
Reports of the rare but serious side effect prompted several countries to suspend the use of the AstraZeneca jab – officially known as Vaxzevria – jab. Its administration was later resumed but with various age restrictions. UK authorities have recommended offering alternative vaccines to people younger than 40.
source: RT
Împotriva articolelor redacției noastre, persoanele nemulțumite pot formula Contestație în termen de 10 zile de la publicarea articolului, la judecătoria Orășenească nr. 1 München Bayern Deutschland, in conformitate cu Legea federală Germană. Considerăm că nu se pot formula acțiuni la instanțele din România deoarece nici o persoană care activează în trustul nostru nu poate fi extrasă de sub jurisdicția federală germană. Considerăm că redacția noastră nu răspunde în fața autorităților din România ci doar celor federale sau civile germane. deoarece legea română nu are efecte de extraneitate asupra redacției chiar dacă subiectul știrilor face obiectul unor evenimente sau persoane din România și sunt scrise în limba română. Limba română nu este izvor de extraneitate a legii.
absolvent WEB DESIGN Academia Britanică de Comunicare Iasi - absolvent COMUNICARE IN AFACERI Academia Britanica de Afaceri si Comunicare -absolvent JURNALISM EDITORIAL - London School University - 2019 inscris la echivalare diploma la Universitatea Politehnica Timisoara - absolvent studii de Drept Universitatea Europeană Drăgan, cursuri in Drept la Universitatea de Vest Timisoara, absolvent studii de proiectare, pastor coordonator in Biserica Protestanta Evanghelica,
Android Developer pe Google Play și plugin developer la Oxwall, creator de teme Wordpress și Oxwall, operator Wordpress, Drupal, Oxwall, Osclass, Moodle, tehnologii HTML și PHP
Nigeria is going to destroy a million doses of AstraZeneca vaccine against Covid-19, a top health official has said, promising that the country will no longer be accepting jabs with short shelf life. The vaccines that were beyond their date of use have been withdrawn and will be destroyed in line with the protocol, Dr. […]
The judge ruled the governor lacks the authority to require those aged two and above to mask up in public New York Governor Kathy Hochul’s order for everyone to wear masks in public was shut down by a New York State Supreme Court judge, who ruled that such decisions must be passed by lawmakers instead. […]
The CEO of US pharma giant Moderna, Stephane Bancel, has come up with a reassuring forecast, suggesting that increasing vaccine production could see the coronavirus pandemic finally coming to an end in mid-2022. “If you look at the industry-wide expansion of production capacities over the past six months, enough doses should be available by the […]
